Brukinsa (Zanubrutinib) is a next-generation Bruton’s tyrosine kinase (BTK) inhibitor developed for the treatment of various B-cell malignancies. It is designed to selectively inhibit BTK, a critical enzyme involved in B-cell receptor signaling that supports the growth, survival, and proliferation of malignant B cells. By blocking this pathway, Brukinsa helps slow disease progression and promotes long-term disease control.
Brukinsa is approved for the treatment of several hematologic cancers, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL), among other indications in specific treatment settings. Its high degree of selectivity allows for potent and sustained BTK inhibition, making it an important option in modern blood cancer therapy.
Administered orally, Brukinsa offers patients a convenient and effective treatment option that can be used as monotherapy or as part of combination treatment regimens. Clinical studies have demonstrated significant improvements in response rates, progression-free survival, and durable disease control across a range of B-cell malignancies.
As an advanced BTK inhibitor, Brukinsa represents a major advancement in precision hematology by delivering targeted therapy designed to address the underlying biology of B-cell cancers. Its proven efficacy, favorable clinical profile, and expanding therapeutic applications continue to make it a valuable treatment option for healthcare professionals and patients worldwide.
Reviews
There are no reviews yet.